FLT F-18 PET/CT in diagnosis, staging and terapy assessmentin tumours with accelereted replicatio

Conditions: patients complying with cancer for whom is mandatory to know the replicative cellular activty
Therapeutic area: Diseases [C] - Cancer [C04]
MedDRA version: 14.1Level: SOCClassification code 10022891Term: InvestigationsSystem Organ Class: 10022891 - Investigations
MedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Registration Number: EUCTR2012-002820-33-IT

Lead Sponsor: CENTRO DI RIFERIMENTO ONCOLOGICO DI BASILICATA

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Authorised-recruitment may be ongoing or finished

Sex: All

Target Recruitment: 100

Inclusion Criteria

patients for whom is mandatory to know cellular replication and to monitor therpy efficacy early
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 70
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 30

Exclusion Criteria

•Age <18 yrs o >90 yrs

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: Impact of F18 FLT PET/CT for replicative evaluation in staging, restaging and therapy assessment of tumours rather than energetic metabolism;Secondary Objective: correlation to angiogenetic markers and EGFR mutations;Primary end point(s): Diagnostic accuracy of F18 FLT PET/CT;Timepoint(s) of evaluation of this end point: 48 months

Secondary Outcome Measures